Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950861 | 1.00 | PREP (0.56) | PREPCAPN1ACECYP1A2ALDH1A1 | |
| SCHEMBL9415824 | 0.90 | CAPN1 (0.57) | PREPCAPN1CYP1A2ALDH1A1 | |
| SCHEMBL14209662 | 0.88 | PREP (0.57) | PREPCAPN1CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL10778616 | 0.84 | PREP (0.52) | PREPCAPN1ACE | |
| SCHEMBL7334484 | 0.81 | PREP (0.72) | PREPACEALDH1A1CYP3A4TSHR | |
| SCHEMBL22209468 | 0.81 | PREP (0.72) | PREPACEALDH1A1CYP3A4TSHR | |
| SCHEMBL7871516 | 0.81 | PREP (0.72) | PREPACEALDH1A1CYP3A4TSHR | |
| SCHEMBL5711352 | 0.80 | PREP (0.57) | PREPCAPN1ACECYP1A2CYP3A4 | |
| SCHEMBL9940046 | 0.79 | NPC1 (0.49) | ALDH1A1AGTR2 | |
| SCHEMBL21874256 | 0.79 | NPC1 (0.49) | ALDH1A1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | PREP 203/4885CAPN1 208/4885ACE 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.